Traws Pharma (TRAW) has delayed its Annual Report filing due to ongoing losses and financing efforts, while projecting $2.8 million in revenue and a net income of around $9.2 million for 2025.

NodeGuardian

2026-04-16 20:20:33

Abstract generation in progress

Traws Pharma (TRAW) has announced a 15-day delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company attributes this delay to recurring operating losses, ongoing efforts to secure financing to meet Nasdaq listing requirements, and the need for KPMG LLP to complete audit procedures following management’s going-concern assessment. Despite the delay, Traws Pharma provided preliminary financial results for 2025, projecting $2.8 million in revenue and a net income of approximately $9.2 million.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes

Reward
2
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
173.63K Popularity
#
Gate13thAnniversaryLive
703.87K Popularity
#
AltcoinsRallyStrong
7.3M Popularity
#
AnthropicvsOpenAIHeatsUp
1.05M Popularity
#
KalshiFacesNevadaRegulatoryClash
453.47K Popularity

Sitemap

Traws Pharma (TRAW) delays 2025 Form 10-K, cites financing and going-concern review

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

AltcoinsRallyStrong

AnthropicvsOpenAIHeatsUp

KalshiFacesNevadaRegulatoryClash

Pin